Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

th year running and the awards ceremony will take place on November 18, 2009 in London.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to have been shortlisted for both the Biotech Company of the Year and Licensing Deal of the Year awards at this prestigious awards event. The nominations are a testament to the significant achievements and progress ThromboGenics has made over the last year. The Company is now in the best position to achieve its aim of becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines. We are very proud to be nominated amongst some of the most successful companies in the industry, and look forward to the results in November."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About Scrip World Pharmaceutical
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 METTLER TOLEDO’s newly improved XS ... balances as well as a dual range ... the new SmartPan™ weighing pan delivers results up to ... all balances, ergonomic design details mean users no longer ... for long periods in front of the balance. Barbara ...
(Date:10/1/2014)... 1, 2014 Pfanstiehl has announced the ... manufactured in the USA ... been recognized for playing a key role in ... of evidence that media supplementation with mannose can ... glycosylation," according to Dr. Christopher Wilcox , ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
(Date:10/1/2014)... This report analyzes the worldwide ... by the following Product Segments: Proteases, Polymerases, ... segments also analyzed are Pharmaceuticals & Diagnostics, ... provides separate comprehensive analytics for the US, ... Latin America. Annual estimates and forecasts are ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... article profiling the significant rise in valuation of ... is true product innovation through focused R&D efforts that's currently ... valuation. , ,While Genentech had revenues of $4.6 billion in ... ,This surpasses Amgen's top position of $72.2 billion, is pretty ...
... and the Endpoint Exchange Network said on Tuesday ... be able to exchange check data and images, starting with ... an IT service provider claiming 4,000 financial clients. Endpoint Exchange ... Metavante , the technology arm of Marshall & Ilsley ...
... Corp. said on Wednesday it has agreed to buy ... spinoff, for $600 million in cash. , ,Bone Care and ... $2 billion and almost 7,000 employees worldwide, plan to complete ... reported healthy quarterly profits and revenues. Bone Care tallied its ...
Cached Biology Technology:Drug innovation beats marketing, patents and mergers 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 3
(Date:9/30/2014)... Pollution in urban and farm runoff in Hawaii is ... finds. , The study, published Tuesday in the ... in the runoff ends up in algae that the ... animals, eyes, flippers and internal organs. , Scientists at ... Oceanic and Atmospheric Administration (NOAA) conducted the study to ...
(Date:9/30/2014)... . , Animals ... such as exposure to predators. Researchers from the Max ... study on different populations of great tits that risk-taking ... High metabolic rates and low temperatures were associated with ... more likely to approach potential predators. , The readiness ...
(Date:9/29/2014)... of gut bacteria called Clostridium ramosum , coupled with ... work is published this week in mBio , the ... , A research team from the German Institute of Human ... bacteria including C. ramosum gained weight when fed ... ramosum were less obese even when consuming a high-fat ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2Gut bacteria promote obesity in mice 2
... NIH-supported scientists will be presenting their latest research findings ... Research in Otolaryngology (ARO). When: February 19-23, 2011 ... Additional Information: Research topics to be presented by scientists ... Communication Disorders (NIDCD) will include: Deafness ...
... will disappear by 2200 as a result of warming ... says a new study by the University of Colorado ... The carbon resides in permanently frozen ground ... warming temperatures, which will impact not only the climate ...
... Scientists are reporting for the first time that ... potential to act as endocrine disruptors, which can interfere ... is not caused by microcystin toxins, long recognized as ... yet unidentified substances. As a result, the scientists are ...
Cached Biology News:NIDCD research at ARO Midwinter Meeting 2NIDCD research at ARO Midwinter Meeting 3NIDCD research at ARO Midwinter Meeting 4NIDCD research at ARO Midwinter Meeting 5NIDCD research at ARO Midwinter Meeting 6NIDCD research at ARO Midwinter Meeting 7Thawing permafrost likely will accelerate global warming 2Thawing permafrost likely will accelerate global warming 3
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
Biology Products: